Back to articles

OpenAI’s MedChemBench Tests AI Reasoning in Medicinal Chemistry

3 min read

OpenAI has introduced MedChemBench, a benchmark designed to test a specific kind of scientific reasoning: can a model connect a molecule’s structure to experimental evidence, explain why compounds behave differently, and decide what might be worth testing next? The set contains 99 problems drawn from 117 papers and patents, with 761 distinct molecular structures. It evaluates reasoning over published research—not whether AI can independently discover a new medicine.

What the benchmark measures

  • Molecular structures: reconstructing atom connections and stereochemistry from chemical drawings and groups.
  • Scientific reasoning: explaining findings or choices using evidence provided in the question.
  • Ranking and selection: choosing or ordering compounds against stated research goals.
  • Property prediction: matching numerical measurements or categories reported in the source material.

The tasks reflect a familiar challenge in medicinal chemistry: a change that improves one property may worsen another. Stronger activity against a biological target does not automatically mean better absorption, permeability, or metabolic stability. In one example, models compare PRMT5 inhibitors across cell activity, cell-barrier permeability, and breakdown in a liver-enzyme assay. Later experimental results show different compounds excelling on different measures. A useful model must reason across those trade-offs rather than optimize for a single result.

Where models did better—and worse

OpenAI says GPT-6 Astra received 95.4% of available structure-reconstruction credit. In one example requiring an 18-atom ring to be preserved, it reconstructed the compound correctly in all ten responses. The company describes structure reconstruction and evidence-based explanations as relative strengths. Compound selection and numerical property predictions were harder, earning only about half the available credit. The page also reports a 58.2% overall score for GPT-5.6 Sol.

There is an important reporting caveat: the page gives GPT-6.2 Astra an overall score of 84.5% in its opening comparison, but later lists 83.3% for GPT-6 Astra at the shared xhigh setting. It does not clearly explain whether the figures refer to different versions or scoring conditions. They should therefore not be treated as directly comparable without clarification.

Why it matters, and what it does not show

The benchmark’s value is its decomposition of a broad claim—whether AI can reason about drug chemistry—into tasks that can be inspected and compared. Its results also expose a gap between recognizing a molecule and making reliable choices about what to test. But the evaluation has clear limits: it uses historical, published material, so prior exposure to the sources cannot be ruled out; each response was a single attempt without tools or feedback; and no new experiments were performed. Strong benchmark scores are not evidence that models can yet make dependable laboratory decisions or accelerate drug development. MedChemBench is best read as a measure of progress on defined reasoning tasks, not a proof of real-world drug-discovery capability.

Web Search

Comments

Checking sign-in status...

Loading comments...

Related articles